FLT3 and acute myeloid leukemia: The approval of midostaurin as adjunct to intensive chemotherapy in AML with activating FLT3 mutations was based on the international multicenter randomized double-blinded phase-III RATIFY trial (n = 717) that investigated the efficacy of midostaurin versus placebo, during induction and consolidation therapy with conventional chemotherapy in young adults (18–59 years) with FLT3-mutated AML, and found an improvement in OS for patients randomized to midostaurin versus placebo (median OS increased from 26 to 75 months and 4-year OS increased from 44 to 51%) [28].